Tetrofosmin as predictor of tumour response

Quarterly Journal of Nuclear Medicine

Volumn 47, Issue 1, 2003, Pages 58-62

  Fuster, D ^a   Vinolas N ^a   Mallafre C ^a   Pavia, J ^a   Martin F ^a   Pons, F ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

99mTc technetium; Drug therapy; Neoplasms; Radionuclide imaging; Radiopharmaceuticals

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN 1; RADIOISOTOPE; TETROFOSMIN; TETROFOSMIN TC 99M; TRACER; DIAGNOSTIC AGENT; MULTIDRUG RESISTANCE PROTEIN; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2 BIS(BIS(2 ETHOXYETHYL)PHOSPHINO)ETHANE; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE;

ADENOCARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CATION TRANSPORT; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DRUG RESPONSE; DRUG TUMOR LEVEL; HODGKIN DISEASE; HUMAN; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONITORING; MULTIDRUG RESISTANCE; NON INVASIVE MEASUREMENT; ONCOLOGY; PREDICTION; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; TUMOR; TUMOR CELL; TUMOR DIAGNOSIS; TUMOR LOCALIZATION; ADULT; AGED; BREAST TUMOR; FEMALE; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; NEOPLASM; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MALE; MELANOMA; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0038354624     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Lind P, Gallowitsch HJ, Langsteger W, Kresnik E, Mikosch P, Gomez I. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1997;38:348-52.
2. Schillaci O, Monteleone F, D'Andrea N, Picardi V, Cangemi R, Cangemi V et al. Technetium-99m tetrofosmin single photon emission computed tomography in the evaluation of suspected lung cancer. Cancer Biother Radiopharm 1999;14:129-34.
3. 99mTc-tetrofosmin scintigraphy for the evaluation of suspicious palpable and non-palpable breast lesions. Breast Cancer Res Treat 2000;62:253-8.
4. Soricelli A, Cuocolo A, Varrone A, Discepolo A, Tedeschi E, Mainenti PP et al. Technetium-99m-tetrofosmin uptake in brain tumors by SPECT: Comparison with tallium-201 imaging. J Nucl Med 1998;39:802-6.
5. Arbab AS, Koizuni K, Toyama K, Arai T, Araki T. Technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 uptake in rat myocardial cells. J Nucl Med 1998;36:226-71.
6. Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, Moore NG. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996;37:1578-82.
7. Fukumoto M, Yoshida D, Hayase N, Kurohara A, Akagi N, Yoshida S. Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma: Technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography study. Cancer 1999;86:1470-9.
8. Utsunomiya K, Ballinger JR, Piquete-Miller M, Rauth AM, Tang W, Su ZF et al. Comparison of the accumulation and efflux of kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 2000;27:1786-92.
9. 99mTc-tetrofosmin for functional imaging of P-glycoprotein modulation in vivo. J Clin Pharmacol 2001; Suppl:39S-47.
10. Zaman GJ, Flens MJ, Van Leusden MR, De Haas M, Mulder HS, Lankelma J et al. The human multidrug resistance-associated protein (MRP) is a plasma membrane drug-efflux pump. Proc Natl Acad Sci 1994;91:8822-6.
11. Bradley G, Juranka PF, Ling V. Mechanism of multidrug resistance. Biochem Biophys Acta 1988;948:87-128.
12. Lee JK, Tsai SC, Ho YJ, Changlai SP, Kao CH. Technetium-99m tetrofosmin scintigraphy for detecting malignant lymphoma. Anticancer Res 2001;21:1509-13.
13. 99mTc-tetrofosmin scintigraphy in Hodgkin's disease. Nucl Med Com 1997;18:252-7.
14. Sun SS, Tsai SC, Ho YJ, Ho ST, Kao CH. Technetium-99m-Tetrofosmin scintigraphy in the prediction of chemotherapy response of untreated malignant lymphomas and comparison with other prognostic factors. Anticancer Res 2001;21:685-8.
15. Ciarmiello A, Del Vecchio S, Silvestro P, Potena MI, Carriero MV, Thomas R et al. Tumor clearance of technetium-99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998;16:1677-83.
16. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Kao CH. Technetium-99m-Tetrofosmin mammoscintigraphy findings related to the expression of P-glycoprotein mediated multidrug resistance. Anticancer Res 2000;20:1467-70.
17. Meghdadi S, Karanikas G, Schlagbauer-Wadl H, Jansen B, Chehne F, Rodrigues M et al. Technetium-99m-tetrofosmin: A new agent for melanoma imaging? Anticancer Res 1998;18:2759-62.
18. 201Tl. Nucl Med Commun 2000;21:1001-8.
19. 99mTc-tetrofosmin imaging: Clinical experience with detecting malignant lesions and monitoring response to therapy. Clin Nucl Med 1998;23:753-7.
20. 99mTc-tetrofosmin y la expresión de P-glicoproteína en cáncer de pulmón no microcítico. Rev Esp Med Nuclear 1998;17:427-34.
21. 99mTc-MIBI imaging in patients with lung cancer. J Nucl Med 2001;42:1476-83.
22. Shiau YC, Tsai SC, Wang JJ, Ho YJ, Ho ST, Kao CH. To predict chemotherapy response using technetium-99m tetrofosmin and compare with p-glycoprotein and multidrug resistance related protein-1 expression in patients with untreated small cell lung cancer. Cancer Lett 2001;169:181-8.
23. Kao CH, Ho YJ, Shen YY, Lee JK. Evaluation of chemotherapy response in patients with small cell lung cancer using technetium-99m-tetrofosmin. Anticancer Res 1999;19:2311-6.
24. 99mTc-tetrofosmin chest imaging. J Nucl Med 2001;42:17-20.